Compare DERM & MSLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DERM | MSLE |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | Canada |
| Employees | N/A | 17 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.3M | 146.9M |
| IPO Year | 2021 | N/A |
| Metric | DERM | MSLE |
|---|---|---|
| Price | $6.40 | $7.30 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $12.67 | N/A |
| AVG Volume (30 Days) | ★ 256.8K | 25.0K |
| Earning Date | 05-13-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.72 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $61,858,000.00 | N/A |
| Revenue This Year | $39.72 | N/A |
| Revenue Next Year | $63.24 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.20 | N/A |
| 52 Week Low | $4.31 | $5.50 |
| 52 Week High | $9.56 | $13.39 |
| Indicator | DERM | MSLE |
|---|---|---|
| Relative Strength Index (RSI) | 64.73 | 49.89 |
| Support Level | $4.84 | $6.73 |
| Resistance Level | $6.71 | $8.59 |
| Average True Range (ATR) | 0.40 | 0.48 |
| MACD | 0.08 | 0.00 |
| Stochastic Oscillator | 85.90 | 38.27 |
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.
Satellos Bioscience Inc is a regenerative medicine company a biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.